Semi-Annual Financial Statements & Other Information

May 31, 2025

ALPS Clean Energy ETF (NYSE Arca: ACES)

ALPS Disruptive Technologies ETF (NYSE Arca: DTEC)

ALPS Electrification Infrastructure ETF (NASDAQ: ELFY)

ALPS Medical Breakthroughs ETF (NYSE Arca: SBIO)

An ALPS Advisors Solution



Table of Contents

Financial Statements and Financial Highlights for Open-End Management Investment Companies

Statement Regarding Basis for Approval of Investment Advisory Contract	34
Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies	33
Proxy Disclosures for Open-End Management Investment Companies	32
Changes in and Disagreements with Accountants for Open-End Management Investment Companies	31
Additional Information	27
Notes to Financial Statements and Financial Highlights	19
Financial Highlights	15
ALPS Electrification Infrastructure ETF	
ALPS Disruptive Technologies ETF	12
Statements of Changes in Net Assets ALPS Clean Energy ETF	1
Statements of Operations	1C
Statements of Assets and Liabilities	9
ALPS Medical Breakthroughs ETF	
ALPS Disruptive Technologies ETFALPS Electrification Infrastructure ETF	
ALPS Clean Energy ETF	1
Schedules of Investments	

Security Description	Shares	Value		
COMMON STOCKS (93.19%)				
Consumer Discretionary (18.28%)				
EVgo, Inc. ^{(a)(b)}	182,316 \$	720,148		
Lucid Group, Inc. ^{(a)(b)}	1,844,119	4,112,384		
Rivian Automotive, Inc. (a)(b)	378,677	5,502,177		
Tesla, Inc. ^(a)	16,082	5,571,769		
Total Consumer Discretionary	_	15,906,478		
Consumer Staples (6.69%)				
Andersons, Inc.	48,857	1,734,912		
Darling Ingredients, Inc. (a)	131,443	4,095,764		
Total Consumer Staples	_	5,830,676		
nergy (2.61%)				
Clean Energy Fuels Corp. (a)(b)	253,645	454,025		
Gevo, Inc. ^{(a)(b)}	346,335	439,845		
Green Plains, Inc. ^(a)	95,229	396,153		
REX American Resources	•			
Corp. ^(a)	23,337	983,421		
Total Energy		2,273,444		
inancials (4.07%)				
HA Sustainable Infrastructure				
Capital, Inc. ^(b)	141,371	3,541,344		
ndustrials (21.09%)				
Ameresco, Inc., Class A ^{(a)(b)}	48,450	667,641		
American Superconductor				
Corp. ^(a)	57,206	1,616,641		
Array Technologies, Inc. (a)(b)	229,861	1,517,083		
Ballard Power Systems, Inc.(a)(b)	382,159	492,985		
ChargePoint Holdings, Inc.(a)(b)	615,392	428,067		
Eos Energy Enterprises, Inc. (a)(b)	335,172	1,394,316		
Fluence Energy, Inc. (a)(b)	96,153	451,919		
NEXTracker, Inc. ^(a)	101,806	5,771,382		
Plug Power, Inc. (a)(b) Shoals Technologies Group,	1,394,251	1,230,705		
Inc., Class A ^(a)	249,006	1,175,308		
Sunrun, Inc. ^{(a)(b)}	333,719	2,499,555		
Willdan Group, Inc. ^(a)	20,452	1,105,431		
otal Industrials		18,351,033		
nformation Technology (14.40%)	60.611	2 022 255		
Enphase Energy, Inc. (a)	68,611	2,839,809		
First Solar, Inc. ^(a)	30,409	4,807,055		
Itron, Inc. ^(a)	39,962	4,619,607		
Wolfspeed, Inc. ^{(a)(b)}	233,679	278,078		
Total Information Technology		12,544,549		

Security Description	Shares	Value
Materials (4.39%)		
Albemarle Corp.(b)	56,020 \$	3,123,676
Aspen Aerogels, Inc.(a)(b)	121,661	700,767
Total Materials		3,824,443
Utilities (21.66%)		
Boralex, Inc., Class A ^(b)	154,581	3,556,033
Clearway Energy, Inc., Class C	123,414	3,797,449
Innergex Renewable Energy,		
Inc. ^(b)	244,344	2,432,134
Northland Power, Inc. ^(b)	310,499	4,629,147
Ormat Technologies, Inc.	59,878	4,450,732
Total Utilities	_	18,865,495
TOTAL COMMON STOCKS		
		81,137,462
(Cost \$218,024,143)	_	
(Cost \$218,024,143) Security Description	Shares	Value
		Value
Security Description		Value
Security Description MASTER LIMITED PARTNERSHIPS (6.57%)		Value
Security Description MASTER LIMITED PARTNERSHIPS (6.57%) Utilities (6.57%)		Value 4,467,524
Security Description MASTER LIMITED PARTNERSHIPS (6.57%) Utilities (6.57%) Brookfield Renewable Partners		
Security Description MASTER LIMITED PARTNERSHIPS (6.57%) Utilities (6.57%) Brookfield Renewable Partners LP	188,010	4,467,524
Security Description MASTER LIMITED PARTNERSHIPS (6.57%) Utilities (6.57%) Brookfield Renewable Partners LP XPLR Infrastructure LP(a)	188,010	4,467,524 1,252,414

May 31, 2025 (Unaudited)

	7 Day Yield	Shares		Value
SHORT TERM INVESTMENTS (:	14.29%)			
Money Market Fund (0.14%)				
State Street Institutional				
Treasury Plus Money				
Market Fund (Premier				
Class)				
(Cost \$124,347)	4.24%	124,347	\$	124,347
Investments Purchased with C	Collateral			
from Securities Loaned (14.14	%)			
State Street Navigator				
Securities Lending				
Government Money Mark	et			
Portfolio, 4.34%				
(Cost \$12,315,640)		12,315,640	\$	12,315,640
TOTAL SHORT TERM INVESTM	IENTS			
(Cost \$12,439,987)				12,439,987
TOTAL INVESTMENTS (114.	04%)			
(Cost \$243,540,342)			\$	99,297,387
LIABILITIES IN EXCESS OF OTH	ER ASSETS (-	-14.04%)		(12,224,689)
NET ASSETS - 100.00%			\$	87,072,698
			_	

⁽a) Non-income producing security.

⁽b) Security, or a portion of the security position is currently on loan. The total market value of securities on loan is \$26,096,875.

Security Description	Shares	Value	Security Description	Shares	Value
COMMON STOCKS (98.87%)			Industrials (continued)		
Communication Services (1.24%)			FANUC Corp.(d)	28,196 \$	757,929
Netflix, Inc. ^(a)	908 \$	1,096,165	Goldwind Science &		
,	<u> </u>	<u> </u>	Technology Co., Ltd., Class		
Consumer Discretionary (3.25%)			Н	1,224,000	949,092
ADT, Inc.	110,683	920,883	Proto Labs, Inc. ^(a)	22,713	839,927
Garmin, Ltd.	3,868	785,088	RELX PLC, Sponsored ADR	16,904	911,464
Tesla, Inc. ^(a)	3,368	1,166,877	Schneider Electric SE	3,319	834,169
Total Consumer Discretionary	_	2,872,848	Sensata Technologies Holding		
,	-	2,072,010	PLC	30,575	796,785
Financials (15.40%)			SS&C Technologies Holdings,		
Adyen NV ^{(a)(b)(c)}	498	955,389	Inc.	10,093	815,615
American Express Co.	3,156	928,022	Stratasys, Ltd. ^(a)	84,126	869,021
Block, Inc. ^(a)	15,029	928,041	Thomson Reuters Corp. (d)	4,738	941,351
Corpay, Inc. ^(a)	2,464	801,071	TransUnion	10,048	860,410
Fidelity National Information	2,101	001,071	Verisk Analytics, Inc.	2,801	879,907
Services, Inc.	11,564	920,610	Vestas Wind Systems A/S	53,362	841,853
Fiserv, Inc. ^(a)	3,852	627,067	Wolters Kluwer NV	5,311	942,546
Global Payments, Inc.	8,805	665,746	Total Industrials		13,745,462
GMO Payment Gateway, Inc. (d)	15,700	966,036		_	
Jack Henry & Associates, Inc.	4,615	836,100	Information Technology (48.43%)		
LendingTree, Inc. ^(a)	17,361	607,982	Adobe, Inc. ^(a)	2,138	887,462
Mastercard, Inc., Class A	1,560	913,536	Alarm.com Holdings, Inc.(a)	13,991	803,083
Moody's Corp.	1,846	884,824	Allegro MicroSystems, Inc. (a)(d)	30,862	782,352
Pagseguro Digital, Ltd., Class A	108,159	963,697	ANSYS, Inc. ^(a)	2,548	842,929
PayPal Holdings, Inc. ^(a)	12,078	848,842	Autodesk, Inc. (a)	3,277	970,385
S&P Global, Inc.	1,688	865,708	Cadence Design Systems, Inc.(a)	3,360	964,555
Visa, Inc., Class A	2,465	900,193	Check Point Software		
Total Financials	2,403		Technologies, Ltd. ^(a)	3,768	862,420
Total Fillaticials	=	13,612,864	Cognex Corp.	26,753	801,787
Hanlib Care (11 000/)			Crowdstrike Holdings, Inc.,		
Health Care (11.98%)	5.047	012 204	Class A ^(a)	2,436	1,148,258
Align Technology, Inc. (a)	5,047	913,204	CyberArk Software, Ltd.(a)	2,516	963,075
Boston Scientific Corp. (a)	8,518	896,605	Dassault Systemes SE	19,368	725,714
Dexcom, Inc. (a)	11,781	1,010,810	Datadog, Inc., Class A ^(a)	8,230	970,152
DiaSorin SpA ^(d)	7,577	785,996	Dynatrace, Inc. ^(a)	17,163	926,974
Globus Medical, Inc. (a)	11,672	690,749	First Solar, Inc. ^(a)	6,097	963,813
HealthEquity, Inc. ^(a)	8,594	864,642	Fortinet, Inc. ^(a)	8,637	879,074
Hologic, Inc. ^(a)	13,386	832,208	Gen Digital, Inc.	30,722	874,963
Insulet Corp. (a)	3,308	1,075,198	Guidewire Software, Inc. (a)	4,603	989,737
Intuitive Surgical, Inc. (a)	1,705	941,740	Intuit, Inc.	1,388	1,045,816
PROCEPT BioRobotics Corp. (a)(d)	14,442	837,636	Itron, Inc. ^(a)	7,765	897,634
ResMed, Inc.	3,690	903,275	Keyence Corp.	2,037	859,844
Smith & Nephew PLC,	20.754	000 746	Klaviyo, Inc. ^(a)	25,301	860,234
Sponsored ADR	28,754	832,716	Nemetschek SE	6,742	936,229
Total Health Care	_	10,584,779	Okta, Inc. ^(a)	7,593	783,370
			Omron Corp. ^(d)	26,300	684,482
Industrials (15.56%)			Open Text Corp.(d)	32,251	913,026
AeroVironment, Inc. ^(a)	6,537	1,163,782	Palo Alto Networks, Inc. ^(a)	4,597	884,555
AutoStore Holdings, Ltd. (a)(b)(c)	863,515	452,594	PTC, Inc. ^(a)	5,261	885,532
Experian PLC	17,867	889,017	Qorvo, Inc. ^(a)	11,690	888,674

Security Description	Shares	Value
Information Technology (continued)		_
Qualys, Inc. ^(a)	6,659	922,604
Renishaw PLC	22,233	769,857
Salesforce, Inc.	2,975	789,476
Samsara, Inc., Class A ^(a)	21,827	1,015,829
SAP SE, Sponsored ADR	3,178	962,489
SenseTime Group, Inc.(a)(b)(c)(d)	3,723,000	664,728
ServiceNow, Inc. ^(a)	1,002	1,013,112
Silicon Laboratories, Inc.(a)	6,694	806,828
Skyworks Solutions, Inc.	12,035	830,776
Snowflake, Inc., Class A ^(a)	5,432	1,117,199
SolarEdge Technologies,		
Inc. ^{(a)(d)}	53,765	960,243
SoundHound AI, Inc.(a)(d)	90,866	918,655
Synopsys, Inc. ^(a)	1,892	877,850
Temenos AG ^(d)	10,372	769,393
Trend Micro, Inc.	11,983	901,463
Workday, Inc., Class A ^(a)	3,409	844,443
Xero, Ltd. ^(a)	8,228	977,431
Xinyi Solar Holdings, Ltd. ^(d)	1,956,000	591,208
Zoom Communications, Inc.,	2,555,555	331,233
Class A ^(a)	11,221	911,706
Zscaler, Inc. ^(a)	4,271	1,177,516
Total Information Technology	-	42,818,935
D 15 1 1 (0.070/)		
Real Estate (0.97%)	0.50	252 272
Equinix, Inc.	968 -	860,378
Utilities (2.04%)		
China Longyuan Power Group		
Corp., Ltd., Class H	1,045,000	867,601
Enlight Renewable Energy,	, ,	•
Ltd. ^(a)	47,715	933,114
Total Utilities	, -	1,800,715
	=	1,000,713
TOTAL COMMON STOCKS		
(Cost \$77,385,238)	-	87,392,146
Security Description	Shares	Value
MASTER LIMITED PARTNERSHIPS (0.95%)		
Utilities (0.95%)		
Brookfield Renewable Partners		
LP	35,422	841,703
.	,	3.2,.33
TOTAL MASTER LIMITED PARTNERSHIPS		
(Cost \$981,612)	<u>-</u>	841,703
	-	

	7 Day Yield	Shares	Value
SHORT TERM INVESTMENTS ((6.69%)		
Money Market Fund (0.08%)			
State Street Institutional			
Treasury Plus Money			
Market Fund (Premier			
Class)			
(Cost \$75,014)	4.24%	75,014	\$ 75,014
Investments Purchased with	Collateral		
from Securities Loaned (6.619	%)		
State Street Navigator			
Securities Lending			
Government Money Mar	ket		
Portfolio, 4.34%			
(Cost \$5,839,629)		5,839,629	\$ 5,839,629
TOTAL SHORT TERM INVESTM	MENTS		
(Cost \$5,914,643)			 5,914,643
TOTAL INVESTMENTS (106	.51%)		
(Cost \$84,281,493)	-		\$ 94,148,492
LIABILITIES IN EXCESS OF OTH	IER ASSETS (-	6.51%)	(5,753,497)
NET ASSETS - 100.00%			\$ 88,394,995

- (a) Non-income producing security.
- (b) Securities exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be sold in the ordinary course of business in transactions exempt from registration, normally to qualified institutional buyers. At period end, the aggregate market value of those securities was \$2,072,711, representing 2.34% of net assets.
- (c) Securities were purchased pursuant to Regulation S under the Securities Act of 1933, which exempts securities offered and sold outside of the United States from registration. Such securities cannot be sold in the United States without either an effective registration statement filed pursuant to the Securities Act of 1933, or pursuant to an exemption from registration. As of May 31, 2025, the market value of those securities was \$2,072,711, representing 2.34% of net assets.
- Security, or a portion of the security position is currently on loan. The total market value of securities on loan is \$7,854,230.

Security Description	Shares	Value	Security Description	Shares	Value
COMMON STOCKS (99.86%)			Information Technology (continued)		
Energy (13.34%)			TE Connectivity PLC	1,914 \$	306,374
Antero Midstream Corp.	14,596 \$	274,113	Trimble, Inc. ^(a)	4,218	300,617
Cameco Corp.	6,347	371,489	Zebra Technologies Corp. (a)	1,102	319,327
Cheniere Energy, Inc.	1,131	268,036	Total Information Technology	·	3,038,145
DT Midstream, Inc.	2,623	274,732			
Enbridge, Inc.	5,666	263,356	Materials (2.73%)		
Kinder Morgan, Inc.	9,235	258,949	Freeport-McMoRan, Inc.	7,966	306,532
ONEOK, Inc.	2,958	239,125	Teck Resources, Ltd., Class B	8,015	296,956
Pembina Pipeline Corp.	6,588	246,918	Total Materials		603,488
Targa Resources Corp.	1,450	228,999			
TC Energy Corp.	5,233	264,999	Technology (0.01%)		
Williams Cos., Inc.	4,288	259,467	Amentum Holdings, Inc. ^(a)	78	1,611
Total Energy		2,950,183	6.7		
rotal Elicity	_	2,330,103	Utilities (38.94%)		
Industrials (31.10%)			AES Corp.	22,756	229,608
Acuity, Inc.	1,044	271,325	Alliant Energy Corp.	3,957	246,244
AECOM	2,668	293,080	Ameren Corp.	2,465	238,809
AMETEK, Inc.	1,537	274,723	American Electric Power Co.,	2, .00	200,000
Comfort Systems USA, Inc.	754	360,585	Inc.	2,291	237,096
Eaton Corp. PLC	928	297,146	CenterPoint Energy, Inc.	6,550	243,922
EMCOR Group, Inc.	667	314,731	CMS Energy Corp.	3,316	232,883
Emerson Electric Co.	2,465	294,272	Consolidated Edison, Inc.	2,204	230,296
Fluor Corp. (a)	7,540	313,513	Constellation Energy Corp.	1,247	381,768
GE Vernova, Inc.	812	384,060	Dominion Energy, Inc.	4,682	265,329
Generac Holdings, Inc. ^(a)	2,291	279,800	DTE Energy Co.	1,827	249,660
Hubbell, Inc.	725	282,446	Duke Energy Corp.	2,001	235,558
Jacobs Solutions, Inc.	2,099	265,103	Edison International	4,437	246,919
MasTec, Inc. (a)	2,175	339,148	Entergy Corp.	2,942	245,010
NEXTracker, Inc. ^(a)	6,293	356,750	Evergy, Inc.	3,607	239,541
nVent Electric PLC	5,146	338,607	Eversource Energy	4,292	278,164
Parsons Corp. (a)	3,915	253,849	Exelon Corp.	5,233	229,310
Quanta Services, Inc.	957	327,830	FirstEnergy Corp.	6,074	254,744
Regal Rexnord Corp.	2,465	328,930	Fortis, Inc.	5,231	255,430
Rockwell Automation, Inc.	1,073	338,585	IDACORP, Inc.	2,059	244,918
Tetra Tech, Inc.	8,307	290,247	NextEra Energy, Inc.	3,625	256,070
Valmont Industries, Inc.	870	276,695	NiSource, Inc.	6,275	248,114
Vertiv Holdings Co.	3,696	398,908	NRG Energy, Inc.	2,708	422,176
Total Industrials		6,880,333	OGE Energy Corp.	5,510	245,030
rotal maderials	_	0,000,333	PG&E Corp.	14,600	246,448
Information Technology (13.74%)			Pinnacle West Capital Corp.	2,614	238,475
Amphenol Corp., Class A	2 870	348,028	PPL Corp.	6,942	241,235
Badger Meter, Inc.	3,870 1,363	348,028	Public Service Enterprise	-	* *
Coherent Corp. ^(a)	4,524	342,150	Group, Inc.	2,987	242,037
Corning, Inc.	4,324 5,945	294,813	Sempra	3,654	287,167
Enphase Energy, Inc. ^(a)	4,698	194,450	Southern Co.	2,679	241,110
First Solar, Inc. (a)	1,943	307,150	Talen Energy Corp. (a)	1,276	311,280
Keysight Technologies, Inc. ^(a)	1,943 1,827	286,912	Vistra Corp.	2,275	365,297
Acysigne reciniologies, IIIC.	1,027	200,312	WEC Energy Group, Inc.	2,262	243,029

ALPS Electrification Infrastructure ETF

Schedule of Investments

May 31, 2025 (Unaudited)

Security Description		Share	s	Value
Utilities (continued)				
Xcel Energy, Inc.		3,480	\$	243,948
Total Utilities			_	8,616,625
TOTAL COMMON STOCKS				
(Cost \$20,540,098)			_	22,090,385
	7 Day Yield	Shares		Value
SHORT TERM INVESTMENTS	(0.03%)			
State Street Institutional				
Treasury Plus Money				
Market Fund (Premier				
Class)	4.24%	7,169	\$	7,169
TOTAL SHORT TERM INVESTI	MENTS			
(Cost \$7,169)				7,169
TOTAL INVESTMENTS (99.	89%)			
(Cost \$20,547,267)			\$	22,097,554
NET LIABILITIES LESS OTHER	ASSETS (0.11%	6)		24,271
NET ASSETS - 100.00%			\$	22,121,825

⁽a) Non-income producing security.

Security Description	Shares	Value	Security Description	Shares	Value
COMMON STOCKS (99.86%)			Biotechnology (continued)		
Biotechnology (81.31%)			Immunome, Inc. (a)(b)	60,908 \$	533,554
4D Molecular Therapeutics,			Intellia Therapeutics, Inc. (a)(b)	75,304	517,338
Inc. ^{(a)(b)}	31,952 \$	115,665	Ironwood Pharmaceuticals,		
ACADIA Pharmaceuticals, Inc.(a)	116,710	2,517,435	Inc. ^{(a)(b)}	113,801	68,178
Agios Pharmaceuticals, Inc. (a)	41,314	1,325,766	iTeos Therapeutics, Inc. (a)	27,898	279,538
Akero Therapeutics, Inc. ^(a)	56,780	2,819,127	Keros Therapeutics, Inc. (a)(b)	28,956	409,727
Aldeyra Therapeutics, Inc. (a)(b)	42,656	91,710	Kyverna Therapeutics, Inc. (a)(b)	31,307	79,833
Alector, Inc. ^(a)	72,973	97,054	Larimar Therapeutics, Inc. (a)	46,227	104,011
Alkermes PLC ^(a)	113,203	3,465,144	MacroGenics, Inc. ^{(a)(b)}	47,373	64,427
Amicus Therapeutics, Inc.(a)	217,037	1,317,415	MannKind Corp. (a)	215,007	892,279
AnaptysBio, Inc. ^{(a)(b)}	22,522	500,664	Merus NV ^(a)	49,884	2,796,997
Anavex Life Sciences Corp.(a)(b)	58,644	441,589	Mineralys Therapeutics, Inc.(a)	33,757	525,934
Annexon, Inc. (a)(b)	80,464	164,147	Mirum Pharmaceuticals,		
Apogee Therapeutics, Inc. (a)(b)	32,429	1,188,199	Inc. ^{(a)(b)}	34,688	1,542,228
Arcturus Therapeutics	32, .23	2,200,200	MoonLake		
Holdings, Inc. ^{(a)(b)}	19,427	243,420	Immunotherapeutics(a)(b)	46,068	1,797,113
Arcus Biosciences, Inc. ^{(a)(b)}	75,090	670,554	Newamsterdam Pharma Co.		
ArriVent Biopharma, Inc. (a)(b)	24,509	520,816	$NV^{(a)}$	76,222	1,380,380
Astria Therapeutics, Inc. ^(a)	42,306	201,377	Novavax, Inc. (a)(b)	111,242	816,516
Aura Biosciences, Inc. ^{(a)(b)}	36,190	212,073	Olema Pharmaceuticals,		
Aurinia Pharmaceuticals, Inc. ^(a)	96,765	758,638	Inc. ^{(a)(b)}	49,163	259,581
Autolus Therapeutics PLC,	30,703	730,030	Praxis Precision Medicines,		
ADR ^(a)	194,483	340,345	Inc. ^{(a)(b)}	14,548	560,825
Avidity Biosciences, Inc. (a)(b)	85,552	2,650,401	ProKidney Corp.(a)	92,690	66,996
BioCryst Pharmaceuticals,	63,332	2,030,401	Protagonist Therapeutics,		
Inc.(a)	149,580	1,607,986	Inc. ^(a)	45,188	2,145,075
Capricor Therapeutics, Inc. (a)(b)	32,359	320,031	Prothena Corp. PLC ^(a)	36,962	169,656
Cargo Therapeutics, Inc. (a)(b)	32,339 32,291	137,237	PTC Therapeutics, Inc. ^(a)	56,067	2,720,371
Cartesian Therapeutics, Inc. (a)(b)	18,885	180,541	Replimune Group, Inc. ^(a)	54,854	492,589
Celcuity, Inc. (a)(b)	28,044	298,108	Rezolute, Inc. ^{(a)(b)}	41,945	172,813
••	•	•	Rhythm Pharmaceuticals,	•	,
Celldex Therapeutics, Inc. (a)(b) CG oncology, Inc. (a)(b)	48,830	965,857	Inc. ^(a)	45,222	2,773,465
017	55,122	1,412,226	Rigel Pharmaceuticals, Inc. (a)	12,757	244,934
Compass Pathways PLC, ADR ^{(a)(b)}	64.400	200 210	Savara, Inc. ^{(a)(b)}	112,723	257,008
	64,499	268,316	Stoke Therapeutics, Inc. (a)(b)	38,848	370,610
Crinetics Pharmaceuticals,	CE 744	2 005 750	Sutro Biopharma, Inc. ^(a)	59,610	53,512
Inc. ^{(a)(b)}	65,741	2,005,758	Tourmaline Bio, Inc. ^{(a)(b)}	17,042	284,261
Day One Biopharmaceuticals,	74 424	455.605	Upstream Bio, Inc. ^{(a)(b)}	38,055	351,248
Inc. ^(a)	71,424	455,685	UroGen Pharma, Ltd. ^{(a)(b)}	31,904	135,273
Denali Therapeutics, Inc. ^(a)	108,960	1,442,630	Vanda Pharmaceuticals, Inc. ^(a)	40,894	177,480
Dianthus Therapeutics, Inc. (a)(b)	23,065	401,100	Vera Therapeutics, Inc. ^{(a)(b)}	45,295	858,340
Disc Medicine, Inc. ^(a)	24,912	1,162,892	Vericel Corp. ^(a)	35,376	1,460,852
Eledon Pharmaceuticals, Inc. (a)	43,269	129,807	Vir Biotechnology, Inc. (a)(b)	100,138	494,682
Enanta Pharmaceuticals, Inc. (a)	15,831	93,878	Viridian Therapeutics, Inc. (a)	59,869	833,376
Erasca, Inc. ^{(a)(b)}	204,768	286,675	Xencor, Inc. ^{(a)(b)}	50,111	400,888
Galapagos NV, Sponsored			Xenon Pharmaceuticals, Inc. ^(a)	54,085	1,560,352
ADR ^{(a)(b)}	47,222	1,358,105	Y-mAbs Therapeutics, Inc. ^(a)	32,429	1,360,332
Ideaya Biosciences, Inc. ^(a)	60,074	1,194,872			
Immunocore Holdings PLC,			Zai Lab, Ltd., ADR ^{(a)(b)}	74,601	2,248,474
ADR ^{(a)(b)}	35,097	1,284,550	Zenas Biopharma, Inc. ^{(a)(b)}	27,396	260,810

May 31, 2025 (Unaudited)

Security Description	Shares	Value	7 Day Yield Shares Value
Biotechnology (continued)			SHORT TERM INVESTMENTS (7.13%)
Zentalis Pharmaceuticals,			Money Market Fund (0.16%)
Inc. ^{(a)(b)}	53,595	\$ 64,850	State Street Institutional
Total Biotechnology	•	66,023,340	Treasury Plus Money
	•		Market Fund (Premier
Health Care Providers & Services (0.57%)			Class)
Fulgent Genetics, Inc. (a)(b)	22,157	459,093	(Cost \$130,293) 4.24% 130,293 \$ 130,293
Pharmaceuticals (17.98%)			
Aclaris Therapeutics, Inc. (a)(b)	76,720	112,011	Investments Purchased with Collateral
Amylyx Pharmaceuticals, Inc.(a)	65,829	339,019	from Securities Loaned (6.97%)
Axsome Therapeutics, Inc. (a)	31,657	3,329,050	State Street Navigator
Edgewise Therapeutics, Inc.(a)	66,498	949,591	Securities Lending
Liquidia Corp. ^{(a)(b)}	61,017	910,374	Government Money Market
MBX Biosciences, Inc. ^{(a)(b)}	25,353	314,884	Portfolio, 4.34%
Neumora Therapeutics, Inc. (a)(b)	111,378	79,780	(Cost \$5,660,324 \$ 5,660,324 \$ 5,660,324
Nuvation Bio, Inc. (a)(b)	239,661	508,081	TOTAL SHORT TERM INVESTMENTS
Pharvaris NV ^{(a)(b)}	35,675	592,205	
Pliant Therapeutics, Inc.(a)(b)	44,069	59,493	(Cost \$5,790,617) 5,790,617
Rapport Therapeutics, Inc. (a)(b)	25,443	210,414	
Structure Therapeutics, Inc.,			TOTAL INVESTMENTS (106.99%)
ADR ^{(a)(b)}	42,251	919,381	(Cost \$107,720,252) \$ 86,875,021
Tarsus Pharmaceuticals, Inc.(a)	27,307	1,172,836	LIABILITIES IN EXCESS OF OTHER ASSETS (-6.99%) (5,678,397)
Theravance Biopharma, Inc.(a)	35,136	321,846	NET ASSETS - 100.00% \$ 81,196,624
Verona Pharma PLC, ADR ^(a)	58,904	4,783,006	NET A33E13 - 100.00%
Total Pharmaceuticals		14,601,971	
	•		(a) Non-income producing security.
TOTAL COMMON STOCKS			(b) Security, or a portion of the security position is currently on
(Cost \$101,929,635)		81,084,404	loan. The total market value of securities on loan is \$21,697,602.

	ALPS Clean Energy ETF	,	ALPS Disruptive Technologies ETF	ALPS Electrification Infrastructure ETF	ALPS Medical Breakthroughs ETF
ASSETS:					
Investments, at value ^(a)	\$ 99,297,387	\$	94,148,492	\$ 22,097,554	\$ 86,875,021
Cash	_		_	1,966	_
Foreign Currency, at value (Cost \$-, \$3, \$- and \$-)	_		3	_	_
Dividends receivable	145,575		125,980	28,305	16,218
Receivable for investments sold	11,423,051		532,423	_	_
Receivable for shares sold	_		2,357,197	_	_
Total Assets	110,866,013		97,164,095	22,127,825	86,891,239
LIABILITIES:					
Payable to adviser	45,615		35,882	6,000	34,291
Payable for investments purchased	1,689,666		2,893,589	_	_
Payable for capital shares redeemed	9,742,394		_	_	_
Payable for collateral upon return of securities loaned	12,315,640		5,839,629	_	5,660,324
Total Liabilities	23,793,315		8,769,100	6,000	5,694,615
NET ASSETS	\$ 87,072,698	\$	88,394,995	\$ 22,121,825	\$ 81,196,624
NET ASSETS CONSIST OF:					
Paid-in capital	\$ 559,302,400	\$	107,887,958	\$ 20,535,214	\$ 243,788,637
Total distributable earnings/(accumulated losses)	(472,229,702)		(19,492,963)	1,586,611	(162,592,013)
NET ASSETS	\$ 87,072,698	\$	88,394,995	\$ 22,121,825	\$ 81,196,624
INVESTMENTS, AT COST	\$ 243,540,342	\$	84,281,493	\$ 20,547,267	\$ 107,720,252
PRICING OF SHARES					
Net Assets	\$ 87,072,698	\$	88,394,995	\$ 22,121,825	\$ 81,196,624
Shares of beneficial interest outstanding (Unlimited number of					
shares authorized, par value \$0.01 per share)	3,575,002		1,875,002	725,002	2,800,000
Net Asset Value, offering and redemption price per share	\$ 24.36	\$	47.14	\$ 30.51	\$ 29.00

⁽a) Includes \$26,096,875, \$7,854,230, \$- and \$21,697,602 of securities on loan.

	ALPS Clean Energy ETF	Å	ALPS Disruptive Technologies ETF	ALPS Electrification Infrastructure ETF ^(a)	ALPS Medical Breakthroughs ETF
INVESTMENT INCOME:					
Dividend income*	\$ 647,384	\$	309,529	\$ 44,702	\$ 3,571
Securities lending income	161,420		13,281	_	73,763
Total investment income	808,804		322,810	44,702	77,334
EXPENSES:					
Investment adviser fees	279,656		219,288	8,432	232,689
Total expenses	279,656		219,288	8,432	232,689
NET INVESTMENT INCOME/(LOSS)	529,148		103,522	36,270	(155,355)
REALIZED AND UNREALIZED GAIN/(LOSS) Net realized gain/(loss) on investments ^(b)	(31,104,051)		2,153,309	-	1,670,737
Net realized gain/(loss) on foreign currency transactions	(204)		5,792	_	_
Total net realized gain/(loss)	(31,104,255)		2,159,101	_	1,670,737
Net change in unrealized appreciation/(depreciation) on investments Net change in unrealized appreciation/(depreciation) on translation of assets and liabilities denominated in foreign	15,492,971		(1,377,151)	1,550,287	(27,973,168)
currencies	(20)		1,947	54	_
Total net change in unrealized appreciation/(depreciation)	15,492,951		(1,375,204)	1,550,341	(27,973,168)
NET REALIZED AND UNREALIZED GAIN/(LOSS) ON					
INVESTMENTS	(15,611,304)		783,897	1,550,341	 (26,302,431)
NET INCREASE/(DECREASE) IN NET ASSETS RESULTING					
FROM OPERATIONS	\$ (15,082,156)	\$	887,419	\$ 1,586,611	\$ (26,457,786)
*Net of foreign tax withholding.	\$ 56,920	\$	20,282	\$ 530	\$ _

 $^{^{(}a)} \quad \textit{The ALPS Electrification Infrastructure ETF commenced operations on April 9, 2025}.$

⁽b) Includes realized gain or loss as a result of in-kind transactions (See Note 4 in Notes to Financial Statements and Financial Highlights).

ALPS Clean Energy ETF

	For the Six Months Ended May 31, 2025 (Unaudited)	For the Year Ended November 30, 2024
OPERATIONS:		
Net investment income	\$ 529,148	\$ 1,826,605
Net realized loss	(31,104,255)	(147,618,871)
Net change in unrealized appreciation/(depreciation)	15,492,951	122,946,030
Net decrease in net assets resulting from operations	(15,082,156)	(22,846,236)
DISTRIBUTIONS TO SHAREHOLDERS:		
From distributable earnings	(534,065)	(987,799)
From tax return of capital	-	(1,743,750)
Total distributions	(534,065)	(2,731,549)
CAPITAL SHARE TRANSACTIONS:		
Proceeds from sale of shares	42,468,272	136,265,280
Cost of shares redeemed	(67,690,233)	(250,753,573)
Net decrease from capital share transactions	(25,221,961)	(114,488,293)
Net decrease in net assets	(40,838,182)	(140,066,078)
NET ASSETS:		
Beginning of period	127,910,880	267,976,958
End of period	\$ 87,072,698	\$ 127,910,880
OTHER INFORMATION:		
CAPITAL SHARE TRANSACTIONS:		
Beginning shares	4,550,002	8,550,002
Shares sold	1,750,000	4,550,000
Shares redeemed	(2,725,000)	(8,550,000)
Shares outstanding, end of period	3,575,002	4,550,002

ALPS Disruptive Technologies ETF

	For the Six Months Ended May 31, 2025 (Unaudited)	For the Year Ended November 30, 2024
OPERATIONS:		
Net investment income	\$ 103,522	\$ 296,642
Net realized gain	2,159,101	2,325,524
Net change in unrealized appreciation/(depreciation)	(1,375,204)	16,074,225
Net increase in net assets resulting from operations	887,419	18,696,391
DISTRIBUTIONS TO SHAREHOLDERS:		
From distributable earnings	(399,326)	(292,162)
Total distributions	(399,326)	(292,162)
CAPITAL SHARE TRANSACTIONS:		
Proceeds from sale of shares	5,686,164	3,055,072
Cost of shares redeemed	(11,132,661)	(25,339,217)
Net decrease from capital share transactions	(5,446,497)	(22,284,145)
Net decrease in net assets	(4,958,404)	(3,879,916)
NET ASSETS:		
Beginning of period	93,353,399	97,233,315
End of period	\$ 88,394,995	\$ 93,353,399
OTHER INFORMATION:		
CAPITAL SHARE TRANSACTIONS:		
Beginning shares	2,000,002	2,525,002
Shares sold	125,000	75,000
Shares redeemed	(250,000)	(600,000)
Shares outstanding, end of period	1,875,002	2,000,002

ALPS Electrification Infrastructure ETF

	For the Period April 9, 2025 (Commencement Operations) to May 31, 2025					
OPERATIONS:						
Net investment income	\$	36,270				
Net change in unrealized appreciation/(depreciation)		1,550,341				
Net increase in net assets resulting from operations		1,586,611				
CAPITAL SHARE TRANSACTIONS:						
Proceeds from sale of shares		20,535,214				
Net increase from capital share transactions		20,535,214				
Net increase in net assets		22,121,825				
NET ASSETS:						
Beginning of period		_				
End of period	\$	22,121,825				
OTHER INFORMATION:						
CAPITAL SHARE TRANSACTIONS:						
Beginning shares		_				
Shares sold		725,002				
Shares outstanding, end of period		725,002				

ALPS Medical Breakthroughs ETF

	For the Six Months Ended May 31, 2025 (Unaudited)	For the Year Ended November 30, 2024
OPERATIONS:		
Net investment loss	\$ (155,355)	\$ (400,845)
Net realized gain	1,670,737	7,550,987
Net change in unrealized appreciation/(depreciation)	(27,973,168)	31,240,527
Net increase/(decrease) in net assets resulting from operations	(26,457,786)	38,390,669
DISTRIBUTIONS TO SHAREHOLDERS:		
From distributable earnings	(3,667,062)	(220,286)
Total distributions	(3,667,062)	(220,286)
CAPITAL SHARE TRANSACTIONS:		
Proceeds from sale of shares	713,612	19,659,637
Cost of shares redeemed	(12,587,901)	(18,323,776)
Net increase/(decrease) from capital share transactions	(11,874,289)	1,335,861
Net increase/(decrease) in net assets	(41,999,137)	39,506,244
NET ASSETS:		
Beginning of period	123,195,761	83,689,517
End of period	\$ 81,196,624	\$ 123,195,761
OTHER INFORMATION:		
CAPITAL SHARE TRANSACTIONS:		
Beginning shares	3,175,000	3,175,000
Shares sold	25,000	550,000
Shares redeemed	(400,000)	(550,000)
Shares outstanding, end of period	2,800,000	3,175,000

		For the Six Months Ended May 31, 2025 (Unaudited)	For the Year Ended November 30, 2024	For the Year Ended November 30, 2023	For the Year Ended November 30, 2022	For the Year Ended November 30, 2021	For the Year Ended November 30, 2020
NET ASSET VALUE, BEGINNING OF PERIOD	\$	28.11	\$ 31.34	\$ 55.74	\$ 73.94	\$ 70.05	\$ 32.23
INCOME/(LOSS) FROM INVESTMENT OPERAT	10	NS:					
Net investment income ^(a)		0.13	0.25	0.47	0.39	0.20	0.25
Net realized and unrealized gain/(loss)		(3.76)	(3.13)	(24.38)	(18.14)	4.11	38.08
Total from investment operations		(3.63)	(2.88)	(23.91)	(17.75)	4.31	38.33
DISTRIBUTIONS:							
From net investment income		(0.12)	(0.13)	(0.40)	(0.19)	(0.17)	(0.18)
Tax return of capital		-	(0.22)	(0.09)	(0.26)	(0.25)	(0.33)
Total distributions		(0.12)	(0.35)	(0.49)	(0.45)	(0.42)	(0.51)
Net increase/(decrease) in net asset value		(3.75)	(3.23)	(24.40)	(18.20)	3.89	37.82
NET ASSET VALUE, END OF PERIOD	\$	24.36	\$ 28.11	\$ 31.34	\$ 55.74	\$ 73.94	\$ 70.05
TOTAL RETURN(b)		(12.95)%	(9.32)%	(43.11)%	(24.00)%	6.16%	120.45%
RATIOS/SUPPLEMENTAL DATA:							
Net assets, end of period (000s)	\$	87,073	\$ 127,911	\$ 267,977	\$ 707,911	\$ 1,014,767	\$ 609,457
Ratio of expenses to average net assets Ratio of net investment income to average		0.55% ^(c)	0.55%	0.55%	0.55%	0.56% ^(d)	0.65%
net assets		1.04% ^(c)	0.85%	1.09%	0.69%	0.26%	0.57%
Portfolio turnover rate(e)		22%	32%	38%	44%	39%	34%

⁽a) Based on average shares outstanding during the period.

⁽b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of the period and redemption at the net asset value on the last day of the period and assuming all distributions are reinvested at reinvestment prices. Total return calculated for a period of less than one year is not annualized.

⁽c) Annualized.

⁽d) Effective January 1, 2021, the Fund's Advisory Fee changed from 0.65% to 0.55%.

⁽e) Portfolio turnover for periods less than one year are not annualized and does not include securities received or delivered from processing creations or redemptions in-kind.

ALPS Disruptive Technologies ETF

Financial Highlights

		For the Six Months Ended May 31, 2025 (Unaudited)	For the Year Ended November 30, 2024		For the Year Ended November 30, 2023	For the Year Ended November 30, 2022	For the Year Ended November 30, 2021	For the Year Ended November 30, 2020
NET ASSET VALUE, BEGINNING OF PERIOD	\$	46.68	\$ 38.51	ç	34.92	\$ 48.23	\$ 42.99	\$ 31.88
INCOME/(LOSS) FROM INVESTMENT OPERA	TIO	NS:						
Net investment income/ (loss) ^(a)		0.05	0.13		0.15	(0.02)	0.15	0.25
Net realized and unrealized gain/(loss)		0.61	8.15		3.45	(13.17)	5.26	11.00
Total from investment operations		0.66	8.28		3.60	(13.19)	5.41	11.25
DISTRIBUTIONS:								
From net investment income		(0.20)	(0.11)		(0.01)	(0.12)	(0.17)	(0.14)
Total distributions		(0.20)	(0.11)		(0.01)	(0.12)	(0.17)	(0.14)
Net increase/(decrease) in net asset value		0.46	8.17		3.59	(13.31)	5.24	11.11
NET ASSET VALUE, END OF PERIOD	\$	47.14	\$ 46.68	Ç	38.51	\$ 34.92	\$ 48.23	\$ 42.99
TOTAL RETURN(b)		1.42%	21.54%		10.31%	(27.41)%	12.60%	35.42%
RATIOS/SUPPLEMENTAL DATA:								
Net assets, end of period (000s)	\$	88,395	\$ 93,353	Ş	97,233	\$ 122,214	\$ 237,546	\$ 150,459
Ratio of expenses to average net assets		0.50% ^(c)	0.50%		0.50%	0.50%	0.50%	0.50%
Ratio of net investment income/(loss) to								
average net assets		0.24% ^(c)	0.30%		0.42%	(0.05)%	0.31%	0.72%
Portfolio turnover rate ^(d)		15%	35%		34%	31%	26%	38%

⁽a) Based on average shares outstanding during the period.

⁽b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of the period and redemption at the net asset value on the last day of the period and assuming all distributions are reinvested at reinvestment prices. Total return calculated for a period of less than one year is not annualized.

⁽c) Annualized.

⁽d) Portfolio turnover for periods less than one year are not annualized and does not include securities received or delivered from processing creations or redemptions in-kind.

ALPS Electrification Infrastructure ETF

Financial Highlights

	(Co	or the Period April 9, 2025 Immencement Operations) to May 31, 2025
NET ASSET VALUE, BEGINNING OF PERIOD	\$	25.00
INCOME/(LOSS) FROM INVESTMENT OPERATIONS:		
Net investment income ^(a)		0.09
Net realized and unrealized gain		5.42
Total from investment operations		5.51
Net increase in net asset value		5.51
NET ASSET VALUE, END OF PERIOD	\$	30.51
TOTAL RETURN ^(b)		13.63%
RATIOS/SUPPLEMENTAL DATA:		
Net assets, end of period (000s)	\$	22,122
Ratio of expenses to average net assets		0.50% ^(c)
Ratio of net investment income to average net assets		2.15% ^(c)
Portfolio turnover rate ^(d)		0%

⁽a) Based on average shares outstanding during the period.

Total return is calculated assuming an initial investment made at the net asset value at the beginning of the period and redemption at the net asset value on the last day of the period and assuming all distributions are reinvested at reinvestment prices. Total return calculated for a period of less than one year is not annualized.

⁽c) Annualized.

⁽d) Portfolio turnover for periods less than one year are not annualized and does not include securities received or delivered from processing creations or redemptions in-kind.

ALPS Medical Breakthroughs ETF

Financial Highlights

		For the					
		Six Months Ended	For the Year Ended				
		May 31, 2025 (Unaudited)	November 30, 2024	November 30, 2023	November 30, 2022	November 30, 2021	November 30, 2020
NET ASSET VALUE, BEGINNING OF PERIOD	\$	38.80	\$ 26.36	\$ 31.29	\$ 42.94	\$ 49.00	\$ 39.51
INCOME/(LOSS) FROM INVESTMENT OPERAT	101	NS:					
Net investment loss ^(a)		(0.05)	(0.13)	(0.10)	(0.13)	(0.18)	(0.13)
Net realized and unrealized gain/(loss)		(8.58)	12.64	(4.83)	(11.52)	(5.88)	9.64
Total from investment operations		(8.63)	12.51	(4.93)	(11.65)	(6.06)	9.51
DISTRIBUTIONS:							
From net investment income		(1.17)	(0.07)	_	_	_	(0.02)
Total distributions		(1.17)	(0.07)	_	-	_	(0.02)
Net increase/(decrease) in net asset value		(9.80)	12.44	(4.93)	(11.65)	(6.06)	9.49
NET ASSET VALUE, END OF PERIOD	\$	29.00	\$ 38.80	\$ 26.36	\$ 31.29	\$ 42.94	\$ 49.00
TOTAL RETURN ^(b)		(22.70)%	47.50%	(15.76)%	(27.13)%	(12.37)%	24.07%
RATIOS/SUPPLEMENTAL DATA:							
Net assets, end of period (000s)	\$	81,197	\$ 123,196	\$ 83,690	\$ 115,009	\$ 188,929	\$ 242,542
Ratio of expenses to average net assets		0.50% ^(c)	0.50%	0.50%	0.50%	0.50%	0.50%
Ratio of net investment loss to average net							
assets		(0.33)% ^(c)	(0.37)%	(0.34)%	(0.39)%	(0.36)%	(0.33)%
Portfolio turnover rate ^(d)		26%	72%	81%	88%	81%	68%

⁽a) Based on average shares outstanding during the period.

⁽b) Total return is calculated assuming an initial investment made at the net asset value at the beginning of the period and redemption at the net asset value on the last day of the period and assuming all distributions are reinvested at reinvestment prices. Total return calculated for a period of less than one year is not annualized.

⁽c) Annualized.

⁽d) Portfolio turnover for periods less than one year are not annualized and does not include securities received or delivered from processing creations or redemptions in-kind.

May 31, 2025 (Unaudited)

1. ORGANIZATION

ALPS ETF Trust (the "Trust"), a Delaware statutory trust, is an open-end management investment company registered under the Investment Company Act of 1940, as amended (the "1940 Act"). As of May 31, 2025, the Trust consisted of twenty-four separate portfolios. Each portfolio represents a separate series of the Trust. This report pertains to the ALPS Clean Energy ETF, ALPS Disruptive Technologies ETF, ALPS Electrification Infrastructure ETF and the ALPS Medical Breakthroughs ETF (each a "Fund" and collectively, the "Funds").

The investment objective of the ALPS Clean Energy ETF is to seek investment results that correspond generally, before fees and expenses, to the performance of the CIBC Atlas Clean Energy Index. The investment objective of the ALPS Disruptive Technologies ETF is to seek investment results that correspond generally, before fees and expenses, to the performance of the Indxx Disruptive Technologies Index. The investment objective of the ALPS Electrification Infrastructure ETF is to seek investment results that correspond generally, before fees and expenses, to the performance of the Ladenburg Thalmann Electrification Infrastructure Index. The investment objective of the ALPS Medical Breakthroughs ETF is to seek investment results that correspond generally, before fees and expenses, to the performance of the S-Network Medical Breakthroughs Index.

ALPS Clean Energy ETF is considered non-diversified and may invest a greater portion of assets in securities of individual issuers than a diversified fund. As a result, changes in the market value of a single investment could cause greater fluctuations in share price than would occur in a diversified fund. ALPS Disruptive Technologies ETF, ALPS Electrification Infrastructure ETF, and ALPS Medical Breakthroughs ETF have elected to qualify as a diversified series of the Trust under the 1940 Act.

With the exception of the ALPS Electrification Infrastructure ETF, each Fund's Shares ("Shares") are listed on the NYSE Arca, Inc. (the "NYSE Arca"). ALPS Electrification Infrastructure ETF is listed on the Nasdaq Stock Market LLC ("NASDAQ"). Each Fund issues and redeems Shares, at net asset value ("NAV") in blocks of 25,000 Shares, each of which is called a "Creation Unit". Creation Units are issued and redeemed principally in-kind for securities included in the Underlying Index. Except when aggregated in Creation Units, Shares are not redeemable securities of the Fund.

Pursuant to the Trust's organizational documents, its Officers and Trustees are indemnified against certain liability arising out of the performance of their duties to the Trust. Additionally, in the normal course of business, the Trust enters into contracts with service providers that contain general indemnification clauses. The Trust's maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Trust that have not yet occurred.

2. SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies consistently followed by the Funds in the preparation of the financial statements. The accompanying financial statements were prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Each Fund is considered an investment company under U.S. GAAP and follows the accounting and reporting guidance applicable to investment companies in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 946. In regards to Financial Accounting Standards Board Update 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures ("ASU 2023-07"), the Chief Operating Decision Maker ("CODM") monitors the operating results of each Fund as a whole. ALPS Advisors, Inc. (the "Adviser") is the CODM for each Fund. Each Fund's financial information is used by the CODM to assess each segment's performance. The CODM has determined that each Fund is a single operating segment as defined by ASU 2023-07 that recognizes revenues and incurs expenses. This is supported by the single investment strategy of each Fund, against which the CODM assesses performance.

A. Portfolio Valuation

Each Fund's NAV is determined daily, as of the close of regular trading on the New York Stock Exchange (the "NYSE"), normally 4:00 p.m. Eastern time, on each day the NYSE is open for trading. The NAV is computed by dividing the value of all assets of the Fund (including accrued interest and dividends), less all liabilities (including accrued expenses and dividends declared but unpaid), by the total number of shares outstanding.

Portfolio securities listed on any exchange other than the NASDAQ are valued at the last sale price on the business day as of which such value is being determined. If there has been no sale on such day, the securities are valued at the mean of the most recent bid and ask prices on such day. Securities traded on the NASDAQ are valued at the NASDAQ Official Closing Price as determined by NASDAQ. Portfolio securities traded on more than one securities exchange are valued at the last sale price on the business day as of which such value is being determined at the close of the exchange representing the principal market for such securities. Portfolio securities traded in the over-the-counter market, but excluding securities traded on the NASDAQ, are valued at the last quoted sale price in such market.

The Funds' investments are valued at market value or, in the absence of market value with respect to any portfolio securities, at fair value according to procedures adopted by the Trust's Board of Trustees (the "Board"). Pursuant to Rule 2a-5 under the 1940 Act, the Board designated the Adviser as the valuation designee ("Valuation Designee") for each Fund to perform the fair value determinations relating to Fund investments. The Adviser may carry out its designated responsibilities as Valuation Designee through various teams and committees. When market quotations are not readily available or when events occur that make established valuation methods unreliable, securities of the Funds may be valued in good faith by the Valuation Designee. These securities generally include, but are not limited to, restricted securities (securities which may not be publicly sold without registration under the Securities Act of 1933) for which a pricing service is unable to provide a market price; securities whose trading has been formally suspended; a security whose market price is not available from a pre-established primary pricing source or the pricing source is not willing to provide a price; a security with respect to which an event has occurred that is most likely to materially affect the value of the security after the market has closed but before the calculation of the Funds' NAV or make it difficult or impossible to obtain a reliable market quotation; or a security whose price, as provided by the pricing service, does not reflect the security's "fair value" due to the security being de-listed from a national exchange or the security's primary trading market is temporarily closed at a time when, under normal conditions, it would be open. As a general principle, the current "fair value" of a security would be the amount which the owner might reasonably expect to receive from the sale on the applicable exchange or principal market. A variety of factors may be considered in determining the fair value of such securities.

B. Fair Value Measurements

Each Fund discloses the classification of its fair value measurements following a three-tier hierarchy based on the inputs used to measure fair value. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability; including assumptions about risk. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability that are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability that are developed based on the best information available.

Valuation techniques used to value the Funds' investments by major category are as follows:

Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party pricing vendor on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the mean of the most recent quoted bid and ask prices on such day and are generally categorized as Level 2 in the hierarchy. Investments in open-end mutual funds are valued at their closing NAV each business day and are categorized as Level 1 in the hierarchy.

Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy.

Various inputs are used in determining the value of each Fund's investments as of the end of the reporting period. When inputs used fall into different levels of the fair value hierarchy, the level in the hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement in its entirety. The designated input levels are not necessarily an indication of the risk or liquidity associated with these investments.

These inputs are categorized in the following hierarchy under applicable financial accounting standards:

- Level 1 Unadjusted quoted prices in active markets for identical investments, unrestricted assets or liabilities that a Fund has the ability to access at the measurement date;
- Level 2 Quoted prices which are not active, quoted prices for similar assets or liabilities in active markets or inputs other than quoted prices that are observable (either directly or indirectly) for substantially the full term of the asset or liability; and
- Level 3 Significant unobservable prices or inputs (including the Fund's own assumptions in determining the fair value of investments) where there is little or no market activity for the asset or liability at the measurement date.

Notes to Financial Statements and Financial Highlights

May 31, 2025 (Unaudited)

The following is a summary of the inputs used to value the Funds' investments as of May 31, 2025:

ALPS Clean Energy ETF

Investments in Securities at Value	evel 1 - Quoted and Inadjusted Prices	Other Significant rvable Inputs	Level 3 - Significan Unobservable Input	Total
Common Stocks*	\$ 81,137,462	\$ _	\$ -	\$ 81,137,462
Master Limited Partnerships*	5,719,938	_	_	5,719,938
Short Term Investments	12,439,987	_	_	12,439,987
Total	\$ 99,297,387	\$ _	\$ -	\$ 99,297,387

ALPS Disruptive Technologies ETF

	Lev	vel 1 - Quoted and	Level 2 - Other Significant	Level 3 - Significant	
Investments in Securities at Value	U	nadjusted Prices	Observable Inputs	Unobservable Inputs	Total
Common Stocks*		87,392,146	_	_	87,392,146
Master Limited Partnerships*		841,703	_	_	841,703
Short Term Investments		5,914,643	_	_	5,914,643
Total	\$	94,148,492	\$ -	\$ -	\$ 94,148,492

ALPS Electrification Infrastructure ETF

	Le	vel 1 - Quoted and	Level 2 - Other Significar	t Level 3 - Significant	
Investments in Securities at Value	U	nadjusted Prices	Observable Inputs	Unobservable Inputs	Total
Common Stocks*		22,090,385	_	-	22,090,385
Short Term Investments		7,169	_	_	7,169
Total	\$	22,097,554	\$ -	\$ -	\$ 22,097,554

ALPS Medical Breakthroughs ETF

	Le	evel 1 - Quoted and	L	evel 2 - Other Significant	: L	evel 3 - Significant			
Investments in Securities at Value	ι	Unadjusted Prices		Unadjusted Prices Observable Inputs		Unobservable Inputs		Total	
Common Stocks*	\$	81,084,404	Ç	-	\$	_	\$	81,084,404	
Short Term Investments		5,790,617		_		_		5,790,617	
Total	\$	86,875,021	ç	_	\$	_	\$	86,875,021	

^{*} For a detailed sector breakdown, see the accompanying Schedule of Investments.

The Funds did not have any securities that used significant unobservable inputs (Level 3) in determining fair value and there were no transfers into or out of Level 3 during the six months ended May 31, 2025.

C. Foreign Investment Risk

The Funds may directly purchase securities of foreign issuers. Investments in non-U.S. issuers may involve unique risks compared to investing in securities of U.S. issuers, including, among others, less liquidity generally, greater market volatility than U.S. securities and less complete financial information and less stringent accounting, corporate governance and financial reporting standards than for U.S. issuers. In addition, adverse political, economic, social, regulatory, business or environmental developments could undermine the value of the Fund's investments or prevent the Fund from realizing the full value of its investments. Financial reporting standards for companies based in foreign markets differ from those in the United States. Finally, the value of the currency of the country in which the Fund has invested could decline relative to the value of the U.S. dollar, which may affect the value of the investment to U.S. investors. The Fund will not enter into transactions to hedge against declines in the value of the Fund's assets that are denominated in foreign currency.

Countries with emerging markets may have relatively unstable governments and may present the risks of nationalization of businesses, restrictions on foreign ownership and prohibitions on the repatriation of assets. The economies of emerging markets countries also may be based on only a few

industries, making them more vulnerable to changes in local or global trade conditions and more sensitive to debt burdens, inflation rates or adverse news and events.

Because foreign markets may be open on different days than the days during which investors may purchase the shares of the Fund, the value of the Funds' securities may change on the days when investors are not able to purchase the shares of the Fund. The value of securities denominated in foreign currencies is converted into U.S. dollars using exchange rates determined daily as of the close of regular trading on the NYSE. Any use of a different rate from the rates used by the Index may adversely affect a Fund's ability to track its Index.

D. Foreign Currency Translation

The books and records of the Funds are maintained in U.S. dollars. Investment valuations and other assets and liabilities initially expressed in foreign currencies are converted each business day into U.S. dollars based upon current exchange rates. The portion of realized and unrealized gains or losses on investments due to fluctuations in foreign currency exchange rates is not separately disclosed and is included in realized and unrealized gains or losses on investments, when applicable.

E. Securities Transactions and Investment Income

Securities transactions are recorded as of the trade date. Realized gains and losses from securities transactions are recorded on the specific identification in accordance with GAAP. Dividend income and capital gains distributions, if any, are recorded on the ex-dividend date, net of any foreign taxes withheld. Interest income, if any, is recorded on the accrual basis.

F. Dividends and Distributions to Shareholders

Dividends from net investment income for the ALPS Disruptive Technologies ETF, the ALPS Global Travel Beneficiaries ETF and the ALPS Medical Breakthroughs ETF, if any, are declared and paid annually or as the Board may determine from time to time. Dividends from net investment income for ALPS Clean Energy ETF, if any, are declared and paid quarterly or as the Board may determine from time to time. Distributions of net realized capital gains earned by the Funds, if any, are distributed at least annually.

G. Federal Tax and Tax Basis Information

The timing and character of income and capital gain distributions are determined in accordance with income tax regulations, which may differ from U.S. GAAP. Reclassifications are made to the Funds' capital accounts for permanent tax differences to reflect income and gains available for distribution (or available capital loss carryforwards) under income tax regulations. The amounts and characteristics of tax basis distributions and composition of distributable earnings/(accumulated losses) are finalized at fiscal year-end; accordingly, tax basis balances have not been determined as of May 31, 2025.

The tax character of the distributions paid during the fiscal year ended November 30, 2024 was as follows:

Fund	Ord	dinary Income	Long-Term	Capital Gain	Return	of Capital
November 30, 2024						
ALPS Clean Energy ETF	\$	987,799	\$	-	\$	1,743,750
ALPS Disruptive Technologies ETF		292,162		_		_
ALPS Medical Breakthroughs ETF		220,286		_		_

The character of distributions made during the year may differ from its ultimate characterization for federal income tax purposes.

Under current law, capital losses maintain their character as short-term or long-term and are carried forward to the next tax year without expiration.

As of November 30, 2024, the following amounts are available as carry forwards to the next tax year:

Fund	Short-Term			Long-Term		
ALPS Clean Energy ETF	\$	119,474,159	\$	167,576,848		
ALPS Disruptive Technologies ETF		9,750,719		20,430,005		
ALPS Medical Breakthroughs ETF		80,707,854		57.273.292		

As of May 31, 2025, the cost of investments for federal income tax purposes and accumulated net unrealized appreciation/(depreciation) on investments were as follows:

			ALPS Disruptive	AL	.PS Electrification		ALPS Medical
Fund	ALI	PS Clean Energy ETF	Technologies ETF	In	frastructure ETF	Ві	reakthroughs ETF
Gross appreciation (excess of value over tax cos	t) \$	4,066,450	\$ 19,287,867	\$	1,708,343	\$	10,682,854
Gross depreciation (excess of tax cost over							
value)		(149,791,793)	(10,460,370)		(158,056)		(32,222,312)
Net unrealized appreciation/(depreciation)	\$	(145,725,343)	\$ 8,827,497	\$	1,550,287	\$	(21,539,458)
Cost of investments for income tax purposes	\$	245,022,730	\$ 85,320,995	\$	20,547,267	\$	108,414,479

The differences between book-basis and tax-basis are primarily due to the deferral of losses from wash sales and investments in partnerships. In addition, certain tax cost basis adjustments are finalized at fiscal year-end and therefore have not been determined as of May 31, 2025.

H. Income Taxes

No provision for income taxes is included in the accompanying financial statements, as each Fund intends to distribute to shareholders all taxable investment income and realized gains and otherwise comply with Subchapter M of the Internal Revenue Code of 1986, as amended, applicable to regulated investment companies. Each Fund evaluates tax positions taken (or expected to be taken) in the course of preparing the Fund's tax returns to determine whether these positions meet a "more-likely-than-not" standard that, based on the technical merits, have a more than fifty percent likelihood of being sustained by a taxing authority upon examination. A tax position that meets the "more-likely-than-not" recognition threshold is measured to determine the amount of benefit to recognize in the financial statements.

As of and during the six months ended May 31, 2025, each Fund did not have a liability for any unrecognized tax benefits. Each Fund files U.S. federal, state, and local tax returns as required. Each Fund's tax returns are subject to examination by the relevant tax authorities until expiration of the applicable statute of limitations, which is generally three years after the filing of the tax return, but may extend to four years in certain jurisdictions. Tax returns for open years have incorporated no uncertain tax positions that require a provision for income taxes.

I. Lending of Portfolio Securities

The Funds have entered into a securities lending agreement with State Street Bank & Trust Co. ("SSB"), the Funds' lending agent. Each Fund may lend their portfolio securities only to borrowers that are approved by SSB. Each Fund will limit such lending to not more than 33 1/3% of the value of its total assets. Each Funds' securities held at SSB as custodian shall be available to be lent except those securities the Fund or ALPS Advisors, Inc. specifically identifies in writing as not being available for lending. The borrower pledges and maintains with each Fund collateral consisting of cash (U.S. Dollars only), securities issued or guaranteed by the U.S. government or its agencies or instrumentalities, and cash equivalents (including irrevocable bank letters of credit) issued by a person other than the borrower or an affiliate of the borrower. The initial collateral received by each Fund is required to have a value of no less than 102% of the market value of the loaned securities for U.S equity securities and a value of no less than 105% of the market value equal to not less than 102% of the current value of the U.S. equity securities on loan and not less than 105% of the current value of the non-U.S. equity securities on loan. The market value of the loaned securities is determined at the close of each business day and any additional required collateral is delivered to each Fund on the next business day. During the term of the loan, each Fund is entitled to all distributions made on or in respect of the loaned securities. Loans of securities are terminable at any time and the borrower, after notice, is required to return borrowed securities within the customary time period for settlement of securities transactions.

Any cash collateral received is reinvested in a money market fund managed by SSB as disclosed in each Fund's Schedule of Investments and is reflected in the Statements of Assets and Liabilities as a payable for collateral upon return of securities loaned. Non-cash collateral, in the form of securities issued or guaranteed by the U.S. government or its agencies or instrumentalities, is not disclosed in a Fund's Statements of Assets and Liabilities or the contractual maturity table below as it is held by the lending agent on behalf of each Fund, and each Fund does not have the ability to re-hypothecate these securities. Income earned by each Fund from securities lending activity is disclosed in the Statement of Operations.

The following is a summary of each Fund's securities lending agreement and related cash and non-cash collateral received as of May 31, 2025:

	Market Value of	Cash Collateral	Non-Cash Collateral	Total Collateral
Fund	Securities on Loan	Received	Received	Received
ALPS Clean Energy ETF	\$ 26,096,875	\$ 12,315,640	\$ 15,676,714	\$ 27,992,354
ALPS Disruptive Technologies ETF	7,854,230	5,839,629	2,332,635	8,172,264
ALPS Medical Breakthroughs ETF	21,697,602	5,660,324	17,117,731	22,778,055

The risks of securities lending include the risk that the borrower may not provide additional collateral when required or may not return the securities when due. To mitigate these risks, each Fund benefits from a borrower default indemnity provided by SSB. SSB's indemnity allows for full replacement of securities lent wherein SSB will purchase the unreturned loaned securities on the open market by applying the proceeds of the collateral or to the extent such proceeds are insufficient or the collateral is unavailable, SSB will purchase the unreturned loan securities at SSB's expense. However, the Funds could suffer a loss if the value of the investments purchased with cash collateral falls below the value of the cash collateral received.

The following tables reflect a breakdown of transactions accounted for as secured borrowings, the gross obligation by the type of collateral pledged or securities loaned, and the remaining contractual maturity of those transactions as of May 31, 2025:

ALPS Clean Energy ETF	Remaining Contractual Maturity of the Agreements					
Securities Lending Transactions	Overnight & Continuous	Up to 30 Days	30-90 Days	Greater than 90 Days	Total	
Common Stocks	\$ 12,315,640	\$ -	\$ -	\$ -	\$ 12,315,640	
Total Borrowings					12,315,640	
Gross amount of recognized liabilities	for securities lending (collateral received)			\$ 12.315.640	

ALPS Disruptive Technologies ETF	Remaining Contractual Maturity of the Agreements				
	Overnight &			Greater than	_
Securities Lending Transactions	Continuous	Up to 30 Days	30-90 Days	90 Days	Total
Common Stocks	\$ 5,839,629	\$ -	\$ -	\$ -	\$ 5,839,629
Total Borrowings					5,839,629
Gross amount of recognized liabilities for securities lending (collateral received)					\$ 5,839,629

ALPS Medical Breakthroughs ETF	Remaining Contractual Maturity of the Agreements				
	Overnight &			Greater than	
Securities Lending Transactions	Continuous	Up to 30 Days	30-90 Days	90 Days	Total
Common Stocks	\$ 5,660,324	\$ -	\$ -	\$ -	\$ 5,660,324
Total Borrowings					5,660,324
Gross amount of recognized liabilities	for securities lending ((collateral received)			\$ 5,660,324

3. INVESTMENT ADVISORY FEE AND OTHER AFFILIATED TRANSACTIONS

ALPS Advisors, Inc. serves as the Funds' investment adviser pursuant to an Investment Advisory Agreement with the Trust on behalf of each Fund (the "Advisory Agreement"). Pursuant to the Advisory Agreement, each Fund pays the Adviser an annual management fee for the services and facilities it provides, payable on a monthly basis as a percentage of the relevant Fund's average daily net assets as set out below. From time to time, the Adviser may waive all or a portion of its fee.

Fund	Advisory Fee
ALPS Clean Energy ETF	0.55%
ALPS Disruptive Technologies ETF	0.50%
ALPS Electrification Infrastructure ETF	0.50%
ALPS Medical Breakthroughs ETF	0.50%

Out of the unitary management fee, the Adviser pays substantially all expenses of each Fund, including licensing fees to the Underlying Index provider, the cost of transfer agency, custody, fund administration, legal, audit, trustees and other services, except for interest expenses, distribution fees or

expenses, brokerage expenses, taxes and extraordinary expenses not incurred in the ordinary course of each Fund's business. The Adviser's unitary management fee is designed to pay substantially all of each Fund's expenses and to compensate the Adviser for providing services for each Fund.

ALPS Fund Services, Inc., an affiliate of the Adviser, is the administrator for the Funds.

Effective April 1, 2025, each Trustee receives (1) a quarterly retainer of \$27,500, (2) a per meeting fee of \$16,500, (3) \$4,000 for any special meeting held outside of a regularly scheduled board meeting, and (4) reimbursement for all reasonable out-of-pocket expenses relating to attendance at meetings. In addition, the Chairman of the Board receives a quarterly retainer of \$7,000, the Chairman of the Audit Committee receives a quarterly retainer of \$4,000, and the Chairman of the Nominating & Governance Committee receives a quarterly retainer of \$2,500, each in connection with their respective roles. Prior to April 1, 2025, each Trustee received (1) a quarterly retainer of \$25,000, (2) a per meeting fee of \$15,000, (3) \$2,500 for any special meeting held outside of a regularly scheduled board meeting, and (4) reimbursement for all reasonable out-of-pocket expenses relating to attendance at meetings. In addition, the Chairman of the Board received a quarterly retainer of \$5,000, the Chairman of the Audit Committee received a quarterly retainer of \$3,000, and the Chairman of the Nominating & Governance Committee received a quarterly retainer of \$2,000, each in connection with their respective roles.

4. PURCHASES AND SALES OF SECURITIES

For the six months ended May 31, 2025, the cost of purchases and proceeds from sales of investment securities, excluding short-term investments and in-kind transactions, were as follows:

Fund	Purchases	Sales
ALPS Clean Energy ETF	\$ 22,585,367	\$ 22,276,649
ALPS Disruptive Technologies ETF	13,372,438	13,612,978
ALPS Medical Breakthroughs ETF	24,565,196	28,446,695

For the six months ended May 31, 2025, the cost of in-kind purchases and proceeds from in-kind sales were as follows:

Fund	Purchases	Sales
ALPS Clean Energy ETF	\$ 42,472,192	\$ 67,680,760
ALPS Disruptive Technologies ETF	5,681,621	11,089,562
ALPS Electrification Infrastructure ETF	20,538,424	_
ALPS Medical Breakthroughs ETF	713,492	12,587,500

For the six months ended May 31, 2025, the in-kind net realized gain/(losses) were as follows:

Fund	Net Realized Gain/(Loss)			
ALPS Clean Energy ETF	\$	(5,997,882)		
ALPS Disruptive Technologies ETF		2,825,987		
ALPS Medical Breakthroughs ETF		2,319,336		

Gains on in-kind transactions are not considered taxable for federal income tax purposes and losses on in-kind transactions are also not deductible for tax purposes.

5. CAPITAL SHARE TRANSACTIONS

Shares are created and redeemed by each Fund only in Creation Unit size aggregations of 25,000 Shares. Only broker-dealers or large institutional investors with creation and redemption agreements called Authorized Participants ("AP") are permitted to purchase or redeem Creation Units from the Funds. Such transactions are generally permitted on an in-kind basis, with a balancing cash component to equate the transaction to the NAV per unit of each Fund on the transaction date. Cash may be substituted equivalent to the value of certain securities generally when they are not available in sufficient quantity for delivery, not eligible for trading by the AP or as a result of other market circumstances.

6. RELATED PARTY TRANSACTIONS

The ALPS Disruptive Technologies ETF engaged in cross trades between other funds in the Trust, or other funds to which the Adviser provides advisory services, during the six months ended May 31, 2025 pursuant to Rule 17a-7 under the 1940 Act. Cross trading is the buying or selling of portfolio securities between funds to which the Adviser serves as the investment adviser or sub-adviser. The Board previously adopted procedures that apply to transactions pursuant to Rule 17a-7. These transactions related to cross trades during the period complied with the requirements set forth by Rule 17a-7 and the Trust's procedures.

Transactions related to cross trades during the year ended May 31, 2025, were as follows:

					Real	ized gain/(loss) on
	Purchase c	ost paid	Sale p	roceeds received		sales
ALPS Disruptive Technologies ETF	\$	-	\$	100,362	\$	(6,805)

7. MARKET RISK

The Funds are subject to investment and operational risks associated with financial, economic and other global market developments and disruptions, including those arising from war, terrorism, market manipulation, government interventions, defaults and shutdowns, political changes or diplomatic developments, public health emergencies (such as the spread of infectious diseases, pandemics and epidemics) and natural/environmental disasters, which can negatively impact the securities markets and cause each Fund to lose value. Securities in each Fund's portfolio may underperform in comparison to securities in general financial markets, a particular financial market or other asset classes due to a number of factors, including inflation (or expectations for inflation), deflation (or expectations for deflation), interest rates, global demand for particular products or resources, market instability, debt crises and downgrades, embargoes, tariffs, sanctions and other trade barriers, regulatory events, other governmental trade or market control programs and related geopolitical events. In addition, the value of the Fund's investments may be negatively affected by the occurrence of global events such as war, terrorism, environmental disasters, natural disasters or events, country instability, and infectious disease epidemics or pandemics.

8. CONCENTRATION RISK

Each Fund seeks to track an underlying index, which itself may have concentration in certain regions, economies, countries, markets, industries or sectors. Underperformance or increased risk in such concentrated areas may result in underperformance or increased risk in the Funds.

9. SUBSEQUENT EVENTS

Subsequent events, if any, after the date of the Statements of Assets and Liabilities have been evaluated through the date the financial statements were issued. Management has determined that there were no subsequent events to report through the issuance of these financial statements

TAX INFORMATION

The Funds designate the following as a percentage of taxable ordinary income distributions, or up to the maximum amount allowable, for the calendar year ended December 31, 2024:

Fund	Qualified Dividend Income	Dividend Received Deduction
ALPS Clean Energy ETF	100.00%	35.14%
ALPS Disruptive Technologies ETF	100.00%	53.29%
ALPS Medical Breakthroughs ETF	0.00%	0.00%

In early 2025, if applicable, shareholders of record received this information for the distributions paid to them by the Funds during the calendar year 2024 via Form 1099. The Funds will notify shareholders in early 2026 of amounts paid to them by the Funds, if any, during the calendar year 2025.

LICENSING AGREEMENT

ALPS Clean Energy ETF

CIBC NTC is the designer of the construction and methodology for the Underlying Index. "CIBC NTC" and "CIBC Atlas Clean Energy Index" are service marks or trademarks of the Index Provider. CIBC NTC acts as brand licensor for the Underlying Index and is not responsible for the descriptions of the Fund that appear herein.

The Fund is not sponsored by CIBC NTC or any of its affiliates. CIBC NTC makes no representation or warranty, express or implied, to the owners of the Fund or any member of the public regarding the advisability of investing in securities or commodities generally or in the Fund particularly. CIBC NTC does not guarantee the quality, accuracy or completeness of the Underlying Index or any Underlying Index data included herein or derived therefrom and assumes no liability in connection with their use. The Underlying Index is determined and composed without regard to the Adviser or the Fund. CIBC NTC has no obligation to take the needs of the Adviser, the Fund or the shareholders of the Fund into consideration in determining, composing or calculating the Underlying Index. CIBC NTC is not responsible for and has not participated in the determination of the timing of, prices at, or quantities of the Fund to be issued or in the determination or calculation of the equation by which the Fund is to be converted into cash. CIBC NTC has no obligation or liability in connection with the administration, marketing or trading of the Fund and is not responsible for and has not participated in the determination of pricing or the timing of the issuance or sale of the Shares of the Fund or in the determination or calculation of the NAV of the Fund.

CIBC NTC has no obligation or liability in connection with the administration, marketing or trading of the Fund. CIBC NTC makes no warranty, express or implied, as to results to be obtained by the Adviser, the Fund, Fund shareholders or any other person or entity from the use of the Underlying Index or any data included therein. CIBC NTC makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the Underlying Index or any data included therein. Without limiting any of the foregoing, in no event shall CIBC NTC have any liability for any special, punitive, indirect, or consequential damages (including lost profits) arising out of matters relating to the use of the Underlying Index, even if notified of the possibility of such damages.

All intellectual property rights in the Underlying Index vests in CIBC NTC.

The Underlying Index is the property of CIBC NTC, which has contracted with S&P Opco, LLC (a subsidiary of S&P Dow Jones Indices LLC) to calculate and maintain the Underlying Index. The Underlying Index is not sponsored by S&P Dow Jones Indices or its affiliates or its third party licensors (collectively, "S&P Dow Jones Indices"). S&P Dow Jones Indices will not be liable for any errors or omissions in calculating the Underlying Index. "Calculated by S&P Dow Jones Indices" and the related stylized mark(s) are service marks of S&P Dow Jones Indices and have been licensed for use by CIBC NTC. S&P® is a registered trademark of Standard & Poor's Financial Services LLC ("SPFS"), and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones").

The Fund is not sponsored, endorsed, sold or promoted by S&P Dow Jones Indices. S&P Dow Jones Indices does not make any representation or warranty, express or implied, to the owners of the Fund or any member of the public regarding the advisability of investing in securities generally or in the Fund particularly or the ability of the Underlying Index to track general market performance. S&P Dow Jones Indices' only relationship to CIBC NTC with respect to the Underlying Index is the licensing of certain trademarks, service marks and trade names of S&P Dow Jones Indices, and the provision of the calculation services related to the Underlying Index. S&P Dow Jones Indices is not responsible for and has not participated in the determination of the prices and amount of the Fund or the timing of the issuance or sale of the Fund or in the determination or calculation of the equation by which the Fund may be converted into cash or other redemption mechanics. S&P Dow Jones Indices has no obligation or liability in connection with the administration,

marketing or trading of the Fund. S&P Dow Jones Indices LLC is not an investment advisor. Inclusion of a security within the Underlying Index is not a recommendation by S&P Dow Jones Indices to buy, sell, or hold such security, nor is it investment advice.

S&P DOW JONES INDICES DOES NOT GUARANTEE THE ADEQUACY, ACCURACY, TIMELINESS AND/OR THE COMPLETENESS OF THE UNDERLYING INDEX OR ANY DATA RELATED THERETO OR ANY COMMUNICATION WITH RESPECT THERETO, INCLUDING, ORAL, WRITTEN, OR ELECTRONIC COMMUNICATIONS. S&P DOW JONES INDICES SHALL NOT BE SUBJECT TO ANY DAMAGES OR LIABILITY FOR ANY ERRORS, OMISSIONS, OR DELAYS THEREIN. S&P DOW JONES INDICES MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE OR AS TO RESULTS TO BE OBTAINED BY CIBC NTC, OWNERS OF THE FUND, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE UNDERLYING INDEX OR WITH RESPECT TO ANY DATA RELATED THERETO. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT WHATSOEVER SHALL S&P DOW JONES INDICES BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES, INCLUDING BUT NOT LIMITED TO, LOSS OF PROFITS, TRADING LOSSES, LOST TIME, OR GOODWILL, EVEN IF THEY HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, WHETHER IN CONTRACT, TORT, STRICT LIABILITY, OR OTHERWISE.

The Index Provider is not affiliated with the Trust, the Adviser or ALPS Portfolio Solutions Distributor, Inc. (the "Distributor"). The Index Provider has entered into a license agreement with the Adviser (the "License Agreement"). The use of the Underlying Index by the Adviser and the Fund is subject to the terms of the License Agreement, which impose certain limitations and conditions on the Fund's ability to use the Underlying Index.

The Adviser does not guarantee the accuracy and/or the completeness of the Underlying Index or any data included therein, and the Adviser shall have no liability for any errors, omissions or interruptions therein. The Adviser makes no warranty, express or implied, as to results to be obtained by the Fund, owners of the Shares of the Fund or any other person or entity from the use of the Underlying Index or any data included therein. The Adviser makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the Underlying Index or any data included therein. Without limiting any of the foregoing, in no event shall the Adviser have any liability for any special, punitive, direct, indirect, or consequential damages (including lost profits) arising out of matters relating to the use of the Underlying Index, even if notified of the possibility of such damages.

ALPS Disruptive Technologies ETF

"Indxx" is a service mark of Indxx, LLC ("Indxx" or the "Index Provider") and has been licensed for use for certain purposes by ALPS Advisors, Inc. (the "Adviser").

The ALPS Disruptive Technologies ETF is not sponsored, endorsed, sold or promoted by Indxx. Indxx makes no representation or warranty, express or implied, to the owners of the ALPS Disruptive Technologies ETF or any member of the public regarding the advisability of investing in securities generally or in the ALPS Disruptive Technologies ETF particularly. Indxx has no obligation to take the needs of ALPS Advisors, Inc. or the shareholders of ALPS Disruptive Technologies ETF into consideration in determining, composing, or calculating the Underlying Index. Indxx is not responsible for and has not participated in the determination of the timing, amount or pricing of the ALPS Disruptive Technologies ETF shares to be issued or in the determination or calculation of the equation by which the ALPS Disruptive Technologies ETF is to be converted into cash. Indxx has no obligation or liability in connection with the administration, marketing or trading of the ALPS Disruptive Technologies ETF.

INDXX MAKES NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE RESULTS TO BE OBTAINED BY ANY PERSON OR ENTITY FROM THE USE OF THE INDEX(ES), TRADING BASED ON THE INDEX(ES), OR ANY DATA INCLUDED THEREIN IN CONNECTION WITH THE PRODUCTS, OR FOR ANY OTHER USE. INDXX EXPRESSLY DISCLAIMS ALL WARRANTIES AND CONDITIONS, EXPRESS, STATUTORY, OR IMPLIED, EXCEPT AS SET FORTH IN THIS AGREEMENT. EXCEPT AS OTHERWISE SPECIFICALLY SET FORTH IN THIS AGREEMENT, INDXX HEREBY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES AND CONDITIONS OF MERCHANTABILITY, TITLE, OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE INDEX(ES) OR ANY DATA INCLUDED THEREIN. INDXX DOES NOT GUARANTEE THE ACCURACY AND/OR THE COMPLETENESS OF ANY DATA SUPPLIED BY IT OR ANY DATA INCLUDED THEREIN. INDXX MAKES NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY THE FUNDS, ITS SHAREHOLDERS OR AFFILIATES, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE DATA SUPPLIED BY INDXX OR ANY DATA INCLUDED THEREIN. INDXX MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE DATA SUPPLIED BY INDXX OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL INDXX HAVE ANY LIABILITY FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

The Adviser does not guarantee the accuracy and/or the completeness of the Underlying Index or any data included therein, and the Adviser shall have no liability for any errors, omissions or interruptions therein. The Adviser makes no warranty, express or implied, as to results to be obtained by the Fund, owners of the Shares of the Fund or any other person or entity from the use of the Underlying Index or any data included therein. Adviser makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the Underlying Index or any data included therein. Without limiting any of the foregoing, in no event shall the Adviser have any liability

for any special, punitive, direct, indirect or consequential damages (including lost profits) arising out of matters relating to the use of the Underlying Index, even if notified of the possibility of such damages.

ALPS Electrification Infrastructure ETF

Ladenburg Thalmann Index, LLC (the "Index Provider") is not affiliated with the ALPS Electrification Infrastructure ETF (the "Fund") or ALPS Advisors, Inc. (the "Adviser"). The Fund is entitled to use the Underlying Index pursuant to a licensing agreement with the Index Provider and the Adviser. The Adviser pays a licensing fee to the Index Provider out of the management fee.

LADENBURG THALMANN INDEX, LLC DOES NOT GUARANTEE THE ACCURACY AND/OR THE COMPLETENESS OF THE LADENBURG THALMANN ELECTRIFICATION INFRASTRUCTURE INDEX (THE "INDEX") OR ANY DATA INCLUDED THEREIN AND LADENBURG THALMANN INDEX, LLC SHALL HAVE NO LIABILITY FOR ANY ERRORS, OMISSIONS, OR INTERRUPTIONS THEREIN. LADENBURG THALMANN INDEX, LLC MAKES NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY LICENSEE, OWNERS OF THE ALPS ELECTRIFICATION INFRASTRUCURE ETF, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE INDEX OR ANY DATA INCLUDED THEREIN. LADENBURG THALMANN INDEX, LLC MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE INDEX OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL LADENBURG THALMANN INDEX, LLC HAVE ANY LIABILITY FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

ALPS Medical Breakthroughs ETF

The Fund is not sponsored, endorsed, sold or promoted by S-Network Global Indexes, Inc. ("Licensor"). Licensor makes no representation or warranty, express or implied, to the owners of the Fund or any member of the public regarding the advisability of investing in securities generally or in the Fund particularly or the ability of the Underlying Index to track the performance of the physical commodities market. Licensor's only relationship to the Licensee is the licensing of certain service marks and trade names of Licensor and of the Underlying Index that is determined, composed and calculated by Licensor without regard to the Licensee or the Fund. Licensor has no obligation to take the needs of the Licensee or the owners of the Fund into consideration in determining, composing or calculating the Underlying Index. Licensor is not responsible for and has not participated in the determination of the timing of, prices at, or quantities of the Fund to be issued or in the determination or calculation of the equation by which the Fund is to be converted into cash. Licensor has no obligation or liability in connection with the administration, marketing or trading of the Fund.

LICENSOR DOES NOT GUARANTEE THE ACCURACY AND/OR THE COMPLETENESS OF THE UNDERLYING INDEX OR ANY DATA INCLUDED THEREIN AND LICENSOR SHALL HAVE NO LIABILITY FOR ANY ERRORS, OMISSIONS, OR INTERRUPTIONS THEREIN. LICENSOR MAKES NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY LICENSEE, OWNERS OF THE FUND, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE UNDERLYING INDEX OR ANY DATA INCLUDED THEREIN. LICENSOR MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE UNDERLYING INDEX OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL LICENSOR HAVE ANY LIABILITY FOR ANY SPECIAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS), EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

Standard & Poor's Custom Indexes serves as calculation agent for the Index. The Fund is not sponsored, endorsed, sold or promoted by Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") or its third party licensors. Neither S&P nor its third party licensors make any representation or warranty, express or implied, to the owners of the Fund or any member of the public regarding the advisability of investing in securities generally or in the Fund particularly or the ability of the Underlying Index to track general stock market performance. S&P's and its third party licensor's only relationship to S-Network Global Indexes, Inc. is the licensing of certain trademarks, service marks and trade names of S&P and/or its third party licensors and for the providing of calculation and maintenance services related to the Underlying Index. Neither S&P nor its third party licensors is responsible for and has not participated in the determination of the prices and amount of the Fund or the timing of the issuance or sale of the Fund or in the determination or calculation of the equation by which the Fund is to be converted into cash. S&P has no obligation or liability in connection with the administration, marketing or trading of the Fund.

NEITHER S&P, ITS AFFILIATES NOR THEIR THIRD PARTY LICENSORS GUARANTEE THE ADEQUACY, ACCURACY, TIMELINESS OR COMPLETENESS OF THE UNDERLYING INDEX OR ANY DATA INCLUDED THEREIN OR ANY COMMUNICATIONS, INCLUDING BUT NOT LIMITED TO, ORAL OR WRITTEN COMMUNICATIONS (INCLUDING ELECTRONIC COMMUNICATIONS) WITH RESPECT THERETO. S&P, ITS AFFILIATES AND THEIR THIRD PARTY LICENSORS SHALL NOT BE SUBJECT TO ANY DAMAGES OR LIABILITY FOR ANY ERRORS, OMISSIONS OR DELAYS THEREIN. S&P MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO ITS TRADEMARKS, THE UNDERLYING INDEX OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT WHATSOEVER SHALL S&P, ITS AFFILIATES OR THEIR THIRD PARTY LICENSORS BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING BUT NOT LIMITED TO, LOSS OF PROFITS, TRADING LOSSES, LOST TIME OR GOODWILL, EVEN IF THEY HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE.

Additional Information

May 31, 2025 (Unaudited)

Standard & Poor's®, and S&P® are registered trademarks of The McGraw-Hill Companies, Inc.; "Calculated by S&P Custom Indices" and its related stylized mark are service marks of The McGraw-Hill Companies, Inc. These marks have been licensed for use by S-Network Global Indexes, Inc.

The Adviser does not guarantee the accuracy and/or the completeness of the Underlying Index or any data included therein, and the Adviser shall have no liability for any errors, omissions or interruptions therein. The Adviser makes no warranty, express or implied, as to results to be obtained by the Fund, owners of the Shares of the Fund or any other person or entity from the use of the Underlying Index or any data included therein. The Adviser makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the Underlying Index or any data included therein. Without limiting any of the foregoing, in no event shall the Adviser have any liability for any special, punitive, direct, indirect, or consequential damages (including lost profits) arising out of matters relating to the use of the Underlying Index, even if notified of the possibility of such damages.

Changes in and Disagreements with Accountants for Open-End Management Investment Companies

May 31, 2025 (Unaudited)

Not applicable for this reporting period.

Proxy Disclosures for

May 31, 2025 (Unaudited)

Open-End Management Investment Companies

Not applicable for this reporting period.

Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies

May 31, 2025 (Unaudited)

The following chart provides certain information about the Trustee fees paid by the Trust for the six months ended May 31, 2025:

	Com	Aggregate Regular pensation From the Trust	 e Special Compensation From the Trust	Total Compensation From the Trust
Mary K. Anstine, Trustee (1)	\$	40,000	-	\$ 40,000
Edmund J. Burke, Trustee		86,500	_	86,500
Jeremy W. Deems, Trustee		88,500	_	88,500
Rick A. Pederson, Trustee		92,500	_	92,500
Joseph F. Keenan, Trustee		82,500	-	82,500
Susan K. Wold, Trustee		82,500	_	82,500
Laton Spahr, President and Trustee*		-	_	_
Total	\$	472,500	\$ -	\$ 472,500

⁽¹⁾ Effective December 31, 2024, Ms. Anstine retired as Trustee of the Trust.

Officers who are employed by the Adviser receive no compensation or expense reimbursement from the Trust.

Pursuant to the Funds' unitary fee arrangements, the Funds do not pay any Trustee fees. The Trustee fees are paid by the Adviser.

^{*} Mr. Spahr, the President of the Trust, is deemed an "interested person" by virtue of his position as an officer of the Trust and of ALPS Advisors, Inc.

Statement Regarding Basis for Approval of Investment Advisory Contract

May 31, 2025 (Unaudited)

At its meeting held on March 12, 2025, the Board of Trustees of the Trust (the "Board" or the "Trustees"), where five of the six Trustees were not an "interested person" of the Trust within the meaning of the Investment Company Act of 1940, as amended (the "Independent Trustees"), evaluated a proposal to approve the Investment Advisory Agreement (the "New Fund Advisory Agreement") between the Trust and ALPS Advisors, Inc. (the "Adviser" or "AAI") with respect to the ALPS Electrification Infrastructure ETF (the "New Fund"). In evaluating the New Fund Advisory Agreement, the Board, including the Independent Trustees, considered various factors, including (i) the nature, extent and quality of the services expected to be provided by the Adviser to the New Fund under the New Fund Advisory Agreement; (ii) the advisory fees and other expenses proposed to be paid by the New Fund compared to those of similar funds managed by other investment advisers; (iii) the expected costs of the services to be provided to the New Fund and the projected profitability to be realized by the Adviser and its affiliates from the Adviser's relationship with the New Fund; (iv) the extent to which economies of scale would be realized if and as the New Fund's assets increase and whether the fee level in the New Fund Advisory Agreement reflects these economies of scale for the benefit of shareholders; and (v) any additional benefits and other considerations.

With respect to the nature, extent and quality of the services to be provided by the Adviser under the New Fund Advisory Agreement, the Board considered and reviewed information concerning the services proposed to be provided under the New Fund Advisory Agreement, the proposed investment strategy for the New Fund, financial information regarding the Adviser and its parent company, information describing the Adviser's current organization and the background and experience of the persons who would be responsible for the day-to-day management of the New Fund, the anticipated financial support of the New Fund, and the nature and quality of services provided to other ETFs, open-end and closed-end funds sponsored by the Adviser. Based upon their review, the Board concluded that the Adviser was qualified to oversee the services to be provided by other service providers and that the services to be provided by the Adviser to the New Fund are expected to be satisfactory.

With respect to the costs of services to be provided and profits to be realized by the Adviser, the Board considered the resources involved in managing the New Fund as well as the fact that the Adviser agreed to pay all of the New Fund's expenses (except for interest expenses, distribution fees or expenses, brokerage expenses, taxes and extraordinary expenses such as litigation and other expenses not incurred in the ordinary course of the New Fund's business) out of the unitary advisory fee. Based on their review, the Board concluded that the expected profitability of the New Fund to the Adviser was not unreasonable.

The Board, including the Independent Trustees, also reviewed comparative fee and expense data provided by FUSE regarding the New Fund. The Trustees noted the proposed advisory fee for services to be provided to the New Fund by the Adviser was 0.50% of the New Fund's average daily net assets. The Trustees also considered that the advisory fee with respect to the New Fund was a unitary one and that, as set forth above, the Adviser had agreed to pay all of the New Fund's expenses (except for interest expenses, marketing fees, distribution fees or expenses, brokerage expenses, taxes and extraordinary expenses such as litigation and other expenses not incurred in the ordinary course of the New Fund's business) out of the unitary fee. The Board considered that, taking into account the impact of the New Fund's unitary advisory fee, the New Fund's expense ratio was above the median of both of its FUSE gross advisory fees peer group and total net expenses peer group. The Board took into account, among other things, the views of the Adviser with respect to the differences between the investment strategy of the New Fund and the investment strategies of the FUSE peer group and the other information available to them, the Board concluded that the advisory fee for the New Fund was reasonable under the circumstances and in light of the quality of services to be provided.

The Board also considered other benefits that may be realized by the Adviser from its relationship with the New Fund and concluded that the advisory fee was reasonable taking into account such benefits.

The Board considered the extent to which economies of scale would be realized as the New Fund grows and whether fee levels reflect a reasonable sharing of such economies of scale for the benefit of the New Fund investors. Because the New Fund is newly organized, the Trustees reviewed the New Fund's proposed unitary advisory fee and anticipated expenses and determined to review economies of scale in the future when the New Fund had attracted assets.

In voting to approve the New Fund Advisory Agreement, the Board concluded that the terms of the New Fund Advisory Agreement are reasonable and fair in light of the services to be performed, the fees paid by certain other funds, expenses to be incurred and such other matters as the Board considered relevant in the exercise of their reasonable business judgment. The Board did not identify any single factor or group of factors as all important or controlling and considered all factors together.



This report has been prepared for shareholders of the ETFs described herein and may be distributed to others only if preceded or accompanied by a prospectus.

ALPS Portfolio Solutions Distributor, Inc., a FINRA member, is the distributor for the ETFs.

